Appendix Table E28. Baseline characteristics of patients with cerebrovascular disease in studies assessing the predictive ability of VerifyNow

| **Author, year [ref]****UID****Country****Study Name** | **Demographics****Total N Enrolled** **Race (% by group)****Male (%)****Age\*** | **Vascular disease history****Previous CAD (%)****Previous heart failure (%)****Previous TIA/stroke (%)****History of PCI or CABG (%):****Stable angina (%)****Unstable angina (%)****Previous PAD (%)****History of MI (%)****STEMI/non-STEMI (%)** | **Vascular risk factors****Dyslipidemia (%)****Smokers (%)****BP(mmHg diastolic/systolic** **HTN (%)****Diabetes (%)** | **Prior medications****(pre-study)****Vitamin K antagonist(%)****Clopidogrel(%)****Aspirin(%)****PPI(%)** | **Procedural data****Stent implantation (%)****Type of stent (%)****Multi- or single-vessel (%)**  | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medications** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ryu, 201021113358South KoreaNR | 57NR24 (42%)Mean +/-SD 60.3 ± 12 years | NRNRNRNRNRNRNRNRNR | Hypercholesterolemia 10 (18%)NRNR13 (23%) | NR100%100%NR | 81%NRNR | Patients receiving a neurointervention | All patients were pre-medicated with 100mg of aspirin and 75 mg of clopidogrel for at least 72 hours before the procedure. |  |
| Kang, 201020223886South KoreaNR | 186NR (?100% Asian)57 (31%)58.3±10.2 | NRNRNRNRNRNRNRNRNRNR | NR; Total cholesterol level (mg/dL): 181.1 ± 36.8; Triglyceride level (mg/dL): 150.3 ± 85.6; HDL cholesterol level (mg/dL): 51.1 ± 17.5; LDL cholesterol level (mg/dL): 109.0 ± 32.5Smoker (current and past smokers who have ever smoked 10 cigarettes per day for at least 1 year): 19%HTN: 51%8% | NRClopidogrel loading (300 mg) only: 136 (73%); Previous other antiplatelet medication plus clopidogrel loading: 29 (16%); Continued clopidogrel medication without loading: 21 (11%)NRNR | NRNRNR | patients undergoing coil embolization for intracranial aneurysms | Clopidogrel: 300-mg LD day before procedure with 89% of patients getting additional 75 mg of CPG on the morning of the procedure ; after procedure, an antiplatelet agent was administered for ≥1 weekAspirin dose/regimen: NR | Heparin during procedure: 3000-IU IV bolus, followed by 1000 IU/h |
| Drazin 201121990814USNR | 52NR20 (38%)62.6+/-14.0 yr (mean/SD) | NRNRNRNRNRNRNR54.5NR | NR3 (6%)NR15 (29%) | NR100%100%29% | 100%NRNR | Patients undergoing neurovascular stenting | Loading dose of 600 mg of clopidogrel and 81 mg of aspirin at least 12 hr before stenting (except in 3 patients with ruptured aneurysm, who received clopidogrel on the day of stenting) and maintenance dose thereafter of 75 mg/day for clopidogrel and 81 mg/day for aspirin. Patients with initial clopidogrel-induced inhibition of 10-19% were given 300 mg more of clopidogrel; those with initial inhibition <10% were given 600 mg more. | Heparin also given but regimen NR, and abciximab given in at least 1 patient. |

\*Mean (standard deviation), unless otherwise stated.
**Abbreviations:** ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors